Management of patients with hepatitis C virus resistance–associated variants to NS5A inhibitors: Where are we now?

Publisher： John Wiley & Sons Inc

E-ISSN： 2046-2484|6|4|82-85

ISSN： 2046-2484

Source： CLINICAL LIVER DISEASE (ELECTRONIC), Vol.6, Iss.4, 2015-10, pp. : 82-85

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of patients with hepatitis C virus genotype 3: Where are we now?

By  

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 6, Iss. 4, 2015-10 ,pp. : 79-81

John Wiley & Sons Inc

Access to resources Recommend Favorite

Analysis of the Resistance of Hepatitis C Virus NS5B Polymerase Inhibitors via Docking and Molecular Dynamics Simulation

By  

MOLECULAR INFORMATICS, Vol. 34, Iss. 2‐3, 2015-02 ,pp. : 78-83

John Wiley & Sons Inc

Access to resources Recommend Favorite

P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325

By  

CHEMMEDCHEM, Vol. 10, Iss. 4, 2015-04 ,pp. : 727-735

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effective epitope identification employing phylogenetic, mutational variability, sequence entropy, and correlated mutation analysis targeting NS5B protein of hepatitis C virus: from bioinformatics to therapeutics

By  

JOURNAL OF MOLECULAR RECOGNITION (ELECTRONIC), Vol. 28, Iss. 8, 2015-08 ,pp. : 492-505

John Wiley & Sons Inc

Access to resources Recommend Favorite

Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS‐650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor

By  

JOURNAL OF PHARMACEUTICAL SCIENCES (ELECTRONIC), Vol. 104, Iss. 9, 2015-09 ,pp. : 2813-2823

John Wiley & Sons Inc

Access to resources Recommend Favorite